Indication

Demyelinating Diseases

2 clinical trials

1 product

1 drug

Clinical trial

Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing Multiple Sclerosis

Status: Recruiting, Estimated PCD: 2027-05-01

Drug

Clinical trial

A Randomized, Double-Blind, Delayed Treatment, Placebo-Controlled Trial to Assess the Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy

Status: Not yet recruiting, Estimated PCD: 2026-10-30

Product